← Human Trials & Peer-Reviewed Studies
The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.
Plain-language guide to PMID 28645983 (2017): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 250 subjects.
Key Facts
- PMID
- 28645983
- Journal
- BMJ open
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Bressendorff I et al. (5 authors)
- DOI
- 10.1136/bmjopen-2017-016795
- Registered trial
- NCT02542319
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
This trial has been approved by the local biomedical research ethics committees and data protection agencies and will be performed in accordance with the latest revision of the Helsinki Declaration.
Who Took Part
The study group was 250 subjects.
By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
Some subjects received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.
More than one site took part, so the subjects came from several places.
Secondary end points include change in pulse wave velocity, bone mineral density, measures of mineral metabolism and clinical end points related to cardiovascular and renal events.
What Was Measured
This trial has been approved by the local biomedical research ethics committees and data protection agencies and will be performed in accordance with the latest revision of the Helsinki Declaration.
PubMed files the paper under topics including Bone Density, Coronary Artery Disease, Denmark, Disease Progression, Glomerular Filtration Rate, Kidney Failure, Chronic and Linear Models.
The authors tagged it with the keywords Magnesium, chronic kidney disease, mineral metabolism, randomised clinical trial and vascular calcification.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 250 subjects.
The publication is from 2017 (BMJ open), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.